Clinical Trial Detail

NCT ID NCT02805660
Title Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

Therapies

Durvalumab + Mocetinostat

Age Groups: adult senior

No variant requirements are available.